Mr Trimboli is an experienced global investor with experience in commodities financing and trading. He has
undertaken investments activities and hold diverse interests in commodities, industrial minerals, real estate
and technology and mental health in Australia and internationally.

Mr Trimboli is the founder of Seefeld Investments with offices in London, Zug and Perth. He has formerly a long
serving senior coal trader at the world’s largest commodities trading group, Glencore International AG and was
a key member of the Glencore team when the group successfully completed its IPO in London and Hong Kong.
He currently holds a Managing Director position in Seefeld Investments Pty Ltd, Non-Executive Chairman in
Audeara Limited (ASX: AUA) and Non-Executive Director positions in the following Companies Quantum
Graphite Limited (ASX: QGL), TradeMutt, Yumm Confectionar, The Reading Switch, Carecircle and Greater
Outcomes, all being companies in revenue generating businesses with developed management teams and on
pathways to profitability.

Dr Keating was the co-founder and Chief Executive Officer of ResApp Health, a digital health company which successfully developed a groundbreaking smartphone technology for accurately diagnosing respiratory diseases based on cough analysis. Dr Keating led the ResApp team through the commercialisation of the company’s technology, commencing with a successful R&D phase through to global regulatory approvals and commercial partnerships, before overseeing the sale of the company to Pfizer in 2022 for $180m. Following the acquisition, he transitioned to the role of Vice President at Pfizer to manage the integration of ResApp’s business. Prior to co-founding ResApp, Dr Keating was the Director of Commercial Engagement at UniQuest, the commercialisation arm of The University of Queensland (UQ) which specialises in industry university collaborations for the UQ’s in-house network of 7,000 world-class researchers. Dr Keating holds a PhD in Mechanical Engineering from The University of Queensland, and an Executive Certificate of Management and Leadership from the MIT Sloan School of Management.

Mr Ntoumenopoulos holds the position as a Director at Tryp Therapeutics. He has a background as the former Managing Director at 21 Corporate, an Australian corporate advisory firm. He is also a seasoned entrepreneur on the lookout for innovative and groundbreaking technologies and businesses. With over 20 years of experience in the financial sector, Mr Ntoumenopoulos has a strong track record in raising capital and providing corporate advice. He was also a founding director of ResApp Health, which Pfizer and Race Oncology later acquired. Mr Ntoumenopoulos holds a Bachelor of Commerce degree from the University of Western Australia, focusing on Money and Banking, Investment Finance, and Electronic Commerce.